This newly formed committee of international
specialists will advise on the scientific and clinical aspects
related to the development of Onxeo’s current and future
programs
Regulatory News:
Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First
North: ONXEO), « Onxeo », a clinical-stage biotechnology company
specializing in the development of innovative drugs targeting tumor
DNA Damage response (DDR) in oncology, today announced the
formation of a new Scientific Advisory Committee of leading
scientific and clinical experts in the fields of DDR, resistance to
treatment and more globally, drug development in oncology. The
Committee will advise and guide the Company as it advances its
proprietary platform of compounds in the DDR field and develops
innovative therapeutics that address unmet medical needs and
improve the management of cancer patients.
“We feel excited and privileged to be able to work with this
eminent group of renowned thought leaders in oncology,” said
Judith Greciet, Chief Executive Officer of Onxeo. “Their
scientific advice and clinical expertise will be extremely useful
to determine the best development strategies for AsiDNA™ and to
leverage its unique properties. Furthermore, their support will be
particularly valuable to design new and differentiated candidates
from our platON™ platform in order to enrich our pipeline of decoy
agonists.”
Gilbert Chu, MD, PhD, Professor of Medicine (Oncology)
and Biochemistry at the Stanford Medical School, commented:
“The decoy-agonist technology that Onxeo is developing is a very
promising new approach which consists in hijacking the DNA damage
response for cancer treatment. AsiDNA™ presents appealing and
original anti-tumoral properties which could lead to new
therapeutic strategies, particularly for cancers with a high unmet
medical need.”
Gilles Favre, PharmD, Medical Biologist, PhD, Director of
CRCT (Toulouse Research Center in Cancerology), concluded:
“Onxeo is addressing a major unmet need in cancer treatment that is
prevention or reversal of tumor drug resistance. The early work
performed by our team on combining AsiDNA™ with targeted therapies
has shown promising results and I look forward to help advance
these developments with my distinguished colleagues.”
The Scientific Advisory Committee will be comprised of the
following members:
Gilbert Chu, MD, PhD, is Professor of Medicine (Oncology)
and Biochemistry at the Stanford Medical School. He received a B.A.
in Physics from Princeton University in 1967, a Ph.D. in Physics
from M.I.T. in 1973, and an M.D. from Harvard Medical School in
1980. Gilbert Chu joined the Stanford faculty in 1987. His notable
contributions include discovering and characterizing proteins
involved in DNA repair and developing instrumentation for assessing
toxicity associated with cancer chemotherapy. His research has also
investigated how cells react to DNA damage from radiation and
chemotherapy.
Gilles Favre, PharmD, Medical Biologist, PhD, Director of
the CRCT (Toulouse Research Center in Cancerology), is currently
Professor of Biochemistry and Medical Biology at the University of
Toulouse and director of the Clinical and Genetic Oncology
Laboratory Medicine at the Institut Universitaire du Cancer de
Toulouse-Oncopole for which he serves as the scientific director.
His research focuses on cancer cell signaling leading to
therapeutic targets identification and translational medicine-based
approaches to discover novel biomarkers. Recently, his work was
focused on reversing resistance to targeted therapy in lung cancers
and melanomas.
Lorenzo Galluzzi, PhD, is Assistant Professor of Cell
Biology in Radiation Oncology with the Department of Radiation
Oncology of the Weill Cornell Medical College (New York, NY, USA),
Honorary Assistant Professor Adjunct at the Yale School of Medicine
(New Haven, CT, USA), Honorary Associate Professor with the Faculty
of Medicine of the University of Paris (Paris, France), and Faculty
Member with several universities in Italy (Ferrara, Padova, Rome).
Lorenzo Galluzzi is best known for major experimental and
conceptual contributions to the fields of tumor metabolism and
tumor immunology, the links between adaptive stress responses in
cancer cells and the activation of a clinically relevant
tumor-targeting immune response.
Ruth Plummer, FMedSci, MD, PhD, is Professor of
Experimental Cancer Medicine at the Northern Institute for Cancer
Research, Newcastle University and an Honorary Consultant in
Medical Oncology in Newcastle Hospitals NHS Foundation Trust. She
leads the Newcastle Experimental Cancer Medicine Centre and also
the CRUK Newcastle Cancer Centre. She runs a phase I all-comers
practice, taking responsibility for one of the most active phase I
unit’s in the UK. Her research interests are in the field of DNA
repair and early phase clinical trials of novel agents, taking the
first in class PARP inhibitor into the clinic in 2003, ATR
inhibitor in 2012 and MCT1 inhibitor in 2014. Her work contributed
to the development and validation of pharmacokinetic and
pharmacodynamic assays in early clinical drug development, assays
that are now embedded in early phase trial design.
Caroline Robert, M.D., Ph.D., is the Head of the
Dermatology Unit at Gustave Roussy and co-director of the Melanoma
Research Unit at Paris-Sud University. She trained at the Paris V
University, France, and completed a research fellowship at Harvard,
Brigham & Women’s hospital in Cancer Immunology and
Immunotherapy. Her main focuses of interest are clinical and
translational research on immunotherapy and targeted therapy.
Caroline Robert is national and international coordinator of many
clinical trials of targeted therapy and immunotherapy from phase I
to III. Her recent work has focused on identification of new
biomarkers for immunotherapy and targeted therapies of patients
with melanoma.
About Onxeo
Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a
clinical-stage biotechnology company developing innovative oncology
drugs targeting tumor DNA-binding functions through unique
mechanisms of action in the sought-after field of DNA Damage
Response (DDR). The Company is focused on bringing early-stage
first-in-class or disruptive compounds from translational research
to clinical proof-of-concept, a value-creating inflection point
appealing to potential partners.
platON™ is Onxeo’s proprietary chemistry platform of
oligonucleotides acting as decoy agonists, which generates new
innovative compounds and broaden the Company’s product
pipeline.
AsiDNA™, the first compound from platON™, is a
first-in-class, highly differentiated DNA Damage Response (DDR)
inhibitor based on a decoy and agonist mechanism acting upstream of
multiple DDR pathways. Translational research has highlighted the
distinctive properties of AsiDNA™, notably its ability to abrogate
tumor resistance to PARP inhibitors regardless of the genetic
mutation status. AsiDNA™ has also shown a strong synergy with other
tumor DNA-damaging agents such as chemotherapy and PARP inhibitors.
The DRIIV-1 (DNA Repair Inhibitor-administered IntraVenously) phase
I study has evaluated AsiDNA™ by systemic administration (IV) in
advanced solid tumors and confirmed the active doses as well as a
favorable human safety profile. The ongoing DRIIV-1b extension
study is evaluating the safety and efficacy of AsiDNA™ at a dose of
600 mg in combination with the reference chemotherapy, carboplatin
-/+ paclitaxel, in advanced metastatic tumors. Preliminary results
from both cohorts showed good tolerability, stabilization of the
disease and an increase in treatment duration compared to previous
treatments. The ongoing REVOCAN phase 1b/2 study evaluates the
effect of AsiDNA™ on the acquired resistance to PARP inhibitor
niraparib in relapsed ovarian cancer (sponsored by Gustave Roussy).
A phase 1b/2 study, AsiDNA™ Children, will be initiated in 2021 to
evaluate the association of AsiDNA™ with radiotherapy in children
with relapsed high-grade glioma (sponsored by Institut Curie).
OX401 is a new drug candidate from platON™, optimized to
be a next-generation PARP inhibitor acting on both the DNA Damage
Response and the activation of immune response, without inducing
resistance. OX401 is undergoing preclinical proof-of-concept
studies, alone and in combination with immunotherapies.
For further information, please visit www.onxeo.com.
Forward looking statements
This communication expressly or implicitly contains certain
forward-looking statements concerning Onxeo and its business. Such
statements involve certain known and unknown risks, uncertainties
and other factors, which could cause the actual results, financial
condition, performance or achievements of Onxeo to be materially
different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Onxeo is
providing this communication as of this date and does not undertake
to update any forward-looking statements contained herein as a
result of new information, future events or otherwise. For a
discussion of risks and uncertainties which could cause actual
results, financial condition, performance or achievements of Onxeo
to differ from those contained in the forward-looking statements,
please refer to the risk factors described in the most recent
Company’s registration document or in any other periodic financial
report and in any other press release, which are available free of
charge on the websites of the Company Group (www.onxeo.com) and/or
the AMF (www.amf-france.org).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210530005014/en/
Onxeo Valerie Leroy, Investor Relations
investors@onxeo.com +33 1 45 58 76 00
Media Relations Nicolas Merigeau NewCap onxeo@newcap.eu
+33 1 44 71 94 98
Investor Relations / Strategic Communication Dušan
Orešanský / Emmanuel Huynh NewCap onxeo@newcap.eu +33 1 44 71 94
92
Certified Adviser for Nasdaq First North Kapital Partner
www.kapitalpartner.dk info@kapitalpartner.dk +45 89 88 78 46